Frontiers in Immunology (Nov 2022)
Proposed new prognostic model using the systemic immune-inflammation index for primary central nervous system lymphoma: A prospective-retrospective multicohort analysis
- Shengjie Li,
- Shengjie Li,
- Shengjie Li,
- Shengjie Li,
- Shengjie Li,
- Shengjie Li,
- Zuguang Xia,
- Zuguang Xia,
- Jiazhen Cao,
- Jiazhen Cao,
- Jinsen Zhang,
- Jinsen Zhang,
- Jinsen Zhang,
- Jinsen Zhang,
- Jinsen Zhang,
- Bobin Chen,
- Tong Chen,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Wei Zhu,
- Wei Zhu,
- Wei Zhu,
- Wei Zhu,
- Wei Zhu,
- Danhui Li,
- Wei Hua,
- Wei Hua,
- Wei Hua,
- Wei Hua,
- Wei Hua,
- Ying Mao,
- Ying Mao,
- Ying Mao,
- Ying Mao,
- Ying Mao
Affiliations
- Shengjie Li
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Shengjie Li
- National Center for Neurological Disorders, Shanghai, China
- Shengjie Li
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Shengjie Li
- Neurosurgical Institute of Fudan University, Shanghai, China
- Shengjie Li
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- Shengjie Li
- Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, Fudan University, Shanghai, China
- Zuguang Xia
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
- Zuguang Xia
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Jiazhen Cao
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
- Jiazhen Cao
- Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China
- Jinsen Zhang
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Jinsen Zhang
- National Center for Neurological Disorders, Shanghai, China
- Jinsen Zhang
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Jinsen Zhang
- Neurosurgical Institute of Fudan University, Shanghai, China
- Jinsen Zhang
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- Bobin Chen
- 0Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
- Tong Chen
- 0Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China
- Xin Zhang
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Xin Zhang
- National Center for Neurological Disorders, Shanghai, China
- Xin Zhang
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Xin Zhang
- Neurosurgical Institute of Fudan University, Shanghai, China
- Xin Zhang
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- Wei Zhu
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Wei Zhu
- National Center for Neurological Disorders, Shanghai, China
- Wei Zhu
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Wei Zhu
- Neurosurgical Institute of Fudan University, Shanghai, China
- Wei Zhu
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- Danhui Li
- 1Department of Pathology, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, China
- Wei Hua
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Wei Hua
- National Center for Neurological Disorders, Shanghai, China
- Wei Hua
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Wei Hua
- Neurosurgical Institute of Fudan University, Shanghai, China
- Wei Hua
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- Ying Mao
- Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
- Ying Mao
- National Center for Neurological Disorders, Shanghai, China
- Ying Mao
- Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China
- Ying Mao
- Neurosurgical Institute of Fudan University, Shanghai, China
- Ying Mao
- Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China
- DOI
- https://doi.org/10.3389/fimmu.2022.1039862
- Journal volume & issue
-
Vol. 13
Abstract
PurposeThe systemic immune-inflammation index (SII) has been considered a novel prognostic biomarker in several types of lymphoma. Our aims were to determine the best statistical relationship between pretreatment SII and survival and to combination of SII and the Memorial Sloan Kettering Cancer Center model (MSKCC) to derive the best prognostic mode in primary central nervous system lymphoma (PCNSL).MethodsPretreatment SII and clinical data in 174 newly diagnosed PCNSL patients were included from two retrospective discovery cohorts (n = 128) and one prospective validation cohort (n = 46). A generalized additive model, Kaplan-Meier curve, and Cox analysis were performed. The high risk versus low risk of SII-MSKCC for the PCNSL cutoff point (0–1 vs. 2–4) was determined by the minimum P-value approach.ResultsThe SII showed a U-shaped relationship with the risk of overall survival (OS; P = 0.006). The patients with low SII or high SII had poorer OS and progression-free survival (PFS) than those with median SII. For PFS and OS, SII-MSKCC was a better predictor than MSKCC alone. The area under the receiver operating characteristic curve of the SII-MSKCC score was 0.84 for OS and 0.78 for PFS in the discovery cohorts. The predictive value of the SII-MSKCC score (OS, 0.88; PFS, 0.95) was verified through the validation cohort. Multivariable Cox analysis and Kaplan-Meier curve showed excellent performance for SII-MSKCC, with significant separation of two groups and better performance than MSKCC alone.ConclusionsWe propose a new prognostic model using SII, age, and Karnofsky score that outperforms MSKCC alone and enables individualized estimates of patient outcome.
Keywords
- Systemic immune-inflammation index
- MSKCC
- primary central nervous system lymphoma
- prognosis
- biomarker
